N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

QLESP Block Versus PENG+LFCN Block for Total Hip Arthroplasty

Sponsor: Huazhong University of Science and Technology • ClinicalTrials.gov ID: NCT07771829

Registry updated: 2026-09-29
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Total hip arthroplasty (THA) is a common surgery to replace damaged hip joints, but many patients experience significant pain after surgery, which can delay recovery and increase the need for strong pain medications (opioids). Nerve blocks are a technique where anesthetic medication is injected near specific nerves to reduce pain. This study compares two different ultrasound-guided nerve block techniques for pain control after THA: the QLESP block (a newer technique that targets two areas with a single injection) and the PENG block combined with the LFCN block (a currently used technique that targets nerves around the hip joint and the outer thigh). Participants in this study will be randomly assigned (like a coin flip) to receive either the QLESP block or the PENG+LFCN block after surgery. The study aims to determine which nerve block provides better pain relief and reduces the need for opioid pain medications in the first 24 hours after surgery. Pain scores, recovery of leg movement, time to first walk, length of hospital stay, and any side effects will also be compared between the two groups.

Interventions

  • QLESP Block (Procedure)
    Ultrasound-guided quadratus lumborum and modified erector spinae plane block. A single-puncture, dual-injection technique at the L4 level. Total volume: 30 mL of 0.375% ropivacaine.
  • PENG+LFCN Block (Procedure)
    Ultrasound-guided pericapsular nerve group block combined with lateral femoral cutaneous nerve block. PENG: 20 mL of 0.375% ropivacaine; LFCN: 10 mL of 0.375% ropivacaine.
  • ropivacaine (Drug)
    Ropivacaine hydrochloride injection, 0.375% solution, administered as a single dose via ultrasound-guided nerve block. Total dose: 112.5 mg (30 mL of 0.375% solution) for the QLESP group; 112.5 mg (30 mL of 0.375% solution) for the PENG+LFCN group.

Eligibility criteria

Inclusion Criteria: * Age 18 to 70 years * Scheduled for elective unilateral total hip arthroplasty via posterolateral approach * American Society of Anesthesiologists (ASA) physical status I-III * Body mass index (BMI) \< 35 kg/m² * Ability to understand pain scoring and patient-controlled analgesia (PCA) use * Willing and able to provide written informed consent Exclusion Criteria: * Allergy or hypersensitivity to local anesthetics (ropivacaine) * Long-term opioid use or chronic pain history requiring regular analgesic use * Active malignancy or infection at the puncture site * Severe psychiatric disorders or communication barriers * Severe cardiopulmonary disease * History of opioid abuse or substance dependence * Participation in another interventional clinical trial within 3 months prior to enrollment * Coagulation abnormalities * Pregnancy or breastfeeding * Any condition that, in the investigator's opinion, would compromise patient safety or data integrity

Conditions

Pain Management Arthroplasty Total Hip Replacement

Locations

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record